DISCUSSION The primary outcome of this investigation revealed that edaravone might potentially contribute to the reduction in the occurrence of CIN in individuals at high risk (CKD Stages 3 and 4) who undergo coronary angiography, although this finding did not reach statistical significance.
← all excerpts
Effectiveness of edaravone in preventing contrast-induced nephropathy in high-risk patients undergoing coronary angiography: A randomized, double-blind trial.
1
—
—